Clinical Trial Update: The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI Patients [Phase 4]

View source ↗

Summary

A Phase 4 trial update assessing the safety and long-term clinical benefit of a PCSK9 inhibitor in patients with ST-elevation myocardial infarction and dyslipid…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemias
• St-elevation Myocardial Infarction

Drugs mentioned

• PCSK9 inhibitor (PCSK9 inhibitor)

Snippet

Sponsor: Hamad Medical Corporation | Conditions: STEMI, Dyslipidemias | Phase 4 | Status: UNKNOWN